Research ExplorerPublicationsAutologous stem cell transplantation for HIV-associated lymp...

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

Standard

Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. / Hübel, Kai; Re, Alessandro; Boumendil, Ariane; Finel, Herve; Hentrich, Marcus; Robinson, Stephen; Wyen, Christoph; Michieli, Mariagrazia; Kanfer, Edward; Diez-Martin, Jose Luis; Balsalobre, Pascual; Vincent, Laure; Schroyens, Wilfried; Santasusana, Josep Maria Ribera; Kröger, Nicolaus; Schiel, Xaver; Cwynarski, Kate; Esquirol, Albert; Sousa, Aida Botelho; Cattaneo, Chiara; Montoto, Silvia; Dreger, Peter.

In: BONE MARROW TRANSPL, Vol. 54, No. 10, 10.2019, p. 1625-1631.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hübel, K, Re, A, Boumendil, A, Finel, H, Hentrich, M, Robinson, S, Wyen, C, Michieli, M, Kanfer, E, Diez-Martin, JL, Balsalobre, P, Vincent, L, Schroyens, W, Santasusana, JMR, Kröger, N, Schiel, X, Cwynarski, K, Esquirol, A, Sousa, AB, Cattaneo, C, Montoto, S & Dreger, P 2019, 'Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party', BONE MARROW TRANSPL, vol. 54, no. 10, pp. 1625-1631. https://doi.org/10.1038/s41409-019-0480-x

APA

Hübel, K., Re, A., Boumendil, A., Finel, H., Hentrich, M., Robinson, S., Wyen, C., Michieli, M., Kanfer, E., Diez-Martin, J. L., Balsalobre, P., Vincent, L., Schroyens, W., Santasusana, J. M. R., Kröger, N., Schiel, X., Cwynarski, K., Esquirol, A., Sousa, A. B., ... Dreger, P. (2019). Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. BONE MARROW TRANSPL, 54(10), 1625-1631. https://doi.org/10.1038/s41409-019-0480-x

Vancouver

Hübel K, Re A, Boumendil A, Finel H, Hentrich M, Robinson S et al. Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. BONE MARROW TRANSPL. 2019 Oct;54(10):1625-1631. https://doi.org/10.1038/s41409-019-0480-x

Bibtex

@article{36e83a3a52d14e81a7d2994c48bd99ed,
title = "Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party",
abstract = "The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24-66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.",
author = "Kai H{\"u}bel and Alessandro Re and Ariane Boumendil and Herve Finel and Marcus Hentrich and Stephen Robinson and Christoph Wyen and Mariagrazia Michieli and Edward Kanfer and Diez-Martin, {Jose Luis} and Pascual Balsalobre and Laure Vincent and Wilfried Schroyens and Santasusana, {Josep Maria Ribera} and Nicolaus Kr{\"o}ger and Xaver Schiel and Kate Cwynarski and Albert Esquirol and Sousa, {Aida Botelho} and Chiara Cattaneo and Silvia Montoto and Peter Dreger",
year = "2019",
month = oct,
doi = "10.1038/s41409-019-0480-x",
language = "English",
volume = "54",
pages = "1625--1631",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party

AU - Hübel, Kai

AU - Re, Alessandro

AU - Boumendil, Ariane

AU - Finel, Herve

AU - Hentrich, Marcus

AU - Robinson, Stephen

AU - Wyen, Christoph

AU - Michieli, Mariagrazia

AU - Kanfer, Edward

AU - Diez-Martin, Jose Luis

AU - Balsalobre, Pascual

AU - Vincent, Laure

AU - Schroyens, Wilfried

AU - Santasusana, Josep Maria Ribera

AU - Kröger, Nicolaus

AU - Schiel, Xaver

AU - Cwynarski, Kate

AU - Esquirol, Albert

AU - Sousa, Aida Botelho

AU - Cattaneo, Chiara

AU - Montoto, Silvia

AU - Dreger, Peter

PY - 2019/10

Y1 - 2019/10

N2 - The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24-66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.

AB - The present study aimed at describing the outcome of patients with HIV-associated lymphomas following autologous hematopoietic stem cell transplantation (autoHCT) in the rituximab and combined antiretroviral therapy (cART) era. Eligible for this retrospective study were HIV-positive patients with lymphoma who received autoHCT between 2007 and 2013. A total of 118 patients were included with a median age of 45 years (range 24-66). Underlying diagnoses were diffuse large B cell lymphoma in 47%, Hodgkin lymphoma in 24%, Burkitt lymphoma in 18%, and plasmablastic lymphoma in 7% of patients. Disease status at autoHCT was complete remission in 44%, partial remission (PR) in 38%, and less than PR in 18% of the patients. With a median follow-up of 4 years, 3-year non-relapse mortality, incidence of relapse, progression-free survival (PFS) and overall survival (OS) were 10%, 27%, 63% and 66%, respectively. By multivariate analysis, disease status less than PR but not CD4+ cell count at the time of autoHCT was a significant predictor of unfavorable PFS and OS. In conclusion, in the era of cART and chemoimmunotherapy, the outcome of autoHCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of the HIV infection.

U2 - 10.1038/s41409-019-0480-x

DO - 10.1038/s41409-019-0480-x

M3 - SCORING: Journal article

C2 - 30804486

VL - 54

SP - 1625

EP - 1631

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 10

ER -